CC
BBIO icon

Centiva Capital’s BridgeBio Pharma BBIO Stock Holding History

Centiva Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,680
Closed -$591K – 1143
2025
Q2 		$591K Buy
+13,680
New +$498K 0.04% 890
2023
Q2 		– Sell
-11,900
Closed -$197K – 1641
2023
Q1 		$197K Buy
+11,900
New +$139K 0.01% 1246
2022
Q1 		– Hold
0
– – – 1626
2021
Q4 		– Hold
0
– – – 1214
2021
Q2 		– Sell
-16,081
Closed -$991K – 1384
2021
Q1 		$991K Buy
16,081
+11,369
+241% +$744K 0.14% 358
2020
Q4 		$335K Buy
+4,712
New +$227K 0.04% 615
2020
Q1 		– Sell
-17,875
Closed -$627K – 626
2019
Q4 		$627K Buy
+17,875
New +$496K 0.11% 378

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return